MedTrace Logo

Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery

NCT06414330 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2025-12-22

No results posted yet for this study

Summary

Low chloride solutions were proved to be better in resuscitation of emergency cases and decrease the resulting hyperchloremic metabolic acidosis in the last decade. In ringers' acetate solutions, there is acetate, which is metabolized in muscles to produce bicarbonate molecules, so neutralizing the ongoing lactic and hyperchloremic metabolic solutions. Both solutions were proved to be superior to normal saline as a fluid therapy plan in most studies with much less ongoing hyperchloremic metabolic acidosis and inflammatory response. In this protocol, modified Del Nido formula will be involved using ringers' acetate instead of plasmalyte solutions and comparing the effects on myocardial protection versus HTK solutions

Conditions

  • Cardiac Ischemia

Interventions

BIOLOGICAL

Ringer acetate based Del Nido cardioplegia

All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.

BIOLOGICAL

HTK

Giving HTK instead of Del Nido

Sponsors & Collaborators

  • Ahmed Ismail Abdelsabour

    collaborator UNKNOWN

  • Ramy Mustafa Abdelgawad Mohamed

    collaborator UNKNOWN

  • Ibrahim Mohamed Imbaby

    collaborator UNKNOWN

  • Amr Ibrahim Abdelaal

    collaborator UNKNOWN

  • Mahmoud Mohamed Atef Sallam

    collaborator UNKNOWN

  • Mohamed, Ahmed Abdelhay Mohamed

    collaborator UNKNOWN

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-11-12
Completion
2025-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06414330 on ClinicalTrials.gov